Purple Book reference family · 351(a) biologic
brolucizumab-dbll (Beovu)
brolucizumab-dbll is an FDA-licensed reference biologic from Novartis Pharmaceuticals Corporation.
351(a) biologicBLA 761125 Novartis Pharmaceuticals Corporation
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2022
Reference product
Originator biologic
351(a)BLA 761125
Beovu brolucizumab-dbll
Novartis Pharmaceuticals Corporation
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference brolucizumab-dbll product.
4 yr 3 mo ago
brolucizumab-dbll: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for brolucizumab-dbll.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
